Background: A novel coronavirus, SARS-CoV-2, has recently emerged and caused the rapid spread of COVID-19 worldwide.
Methods: We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between February 1 and February 29, 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen.
Results: 112 patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhoea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both IgM and IgG, 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post disease onset, and lasted for one month and gradually decreased, while IgG antibody was produced 10 days after infection, and lasted for a longer time. However, no significant difference in level of IgM and IgG antibody between positive and negative patients of nucleic acid test after treatment was found.
Conclusions: Our results indicate that serological tests could be powerful approach for the early diagnosis of COVID-19.
Keywords: COVID-19; SARS-CoV-2; antibody; humoral immunity; serological test.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: email@example.com.
Antibody Detection and Dynamic Characteristics in Patients with COVID-19.Clin Infect Dis. 2020 Apr 19:ciaa461. doi: 10.1093/cid/ciaa461. Online ahead of print. Clin Infect Dis. 2020. PMID: 32306047 Free PMC article.
Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.J Appl Lab Med. 2020 May 19:jfaa079. doi: 10.1093/jalm/jfaa079. Online ahead of print. J Appl Lab Med. 2020. PMID: 32428207
Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.Endocr Metab Immune Disord Drug Targets. 2020 Apr 27. doi: 10.2174/1871530320666200427112902. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 32338224
COVID-19 (Novel Coronavirus 2019) - recent trends.Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2006-2011. doi: 10.26355/eurrev_202002_20378. Eur Rev Med Pharmacol Sci. 2020. PMID: 32141569 Review.
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Mil Med Res. 2020. PMID: 32169119 Free PMC article. Review.